Quince Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results significantly missed consensus on profitability metrics, primarily driven by the $59.0M acquisition of Orphai Therapeutics. GAAP Net Loss of $75.5M was much wider than the $18.9M expected, while Diluted EPS of -$12.31 aligned with the mean estimate of -$12.29 due to a lower share count from two reverse stock splits. A massive $115M private placement financing strengthened the balance sheet to $116M in cash, extending the runway through 2028.